Results 221 to 230 of about 5,890,604 (383)
Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann +15 morewiley +1 more sourceThe genome sequence of Drosophila melanogaster.
Science, 2000 M. Adams, S. Celniker, R. Holt, C. Evans, J. Gocayne, P. Amanatides, S. Scherer, P. Li, R. Hoskins, R. Galle, R. George, S. Lewis, S. Richards, M. Ashburner, S. Henderson, G. Sutton, J. Wortman, M. Yandell, Q. Zhang, L. Chen, R. Brandon, Y. Rogers, R. Blazej, M. Champe, B. Pfeiffer, K. Wan, C. Doyle, E. G. Baxter, G. Helt, C. Nelson, G. Gábor, J. F. Abril, A. Agbayani, H. An, C. Andrews-Pfannkoch, D. Baldwin, R. Ballew, A. Basu, J. Baxendale, L. Bayraktaroglu, E. Beasley, K. Beeson, P. Benos, B. Berman, D. Bhandari, S. Bolshakov, D. Borkova, M. Botchan, J. Bouck, P. Brokstein, P. Brottier, K. C. Burtis, D. Busam, H. Butler, É. Cadieu, A. Center, I. Chandra, J. Cherry, S. Cawley, C. Dahlke, L. Davenport, P. Davies, B. de Pablos, A. Delcher, Z. Deng, A. D. Mays, I. Dew, S. Dietz, K. Dodson, L. Doup, M. Downes, S. Dugan-Rocha, B. Dunkov, P. Dunn, K. Durbin, C. Evangelista, C. Ferraz, S. Ferriera, W. Fleischmann, C. Fosler, A. Gabrielian, N. Garg, W. Gelbart, K. Glasser, A. Glodek, F. Gong, J. H. Gorrell, Z. Gu, P. Guan, M. Harris, N. Harris, D. Harvey, T. J. Heiman, J. Hernandez, J. Houck, D. Hostin, K. Houston, T. Howland, M. Wei, C. Ibegwam, M. Jalali, F. Kalush, G. Karpen, Z. Ke, J. Kennison, K. Ketchum, B. E. Kimmel, C. Kodira, C. Kraft, S. Kravitz, D. Kulp, Z. Lai, P. Lasko, Y. Lei, A. Levitsky, J. Li, Z. Li, Y. Liang, X. Lin, X. Liu, B. Mattei, T. McIntosh, M. P. McLeod, D. McPherson, G. Merkulov, N. Milshina, C. Mobarry, J. Morris, A. Moshrefi, Stephen M. Mount, M. Moy, B. Murphy, L. Murphy, D. Muzny, D. Nelson, D. Nelson, K. Nelson, K. Nixon, D. Nusskern, J. Pacleb, M. Palazzolo, G. Pittman, S. Pan, J. Pollard, V. Puri, M. G. Reese, K. Reinert, K. Remington, R. Saunders, F. Scheeler, H. Shen, B. Shue, I. Sidén-Kiamos, M. Simpson, M. Skupski, T. Smith, E. Spier, A. Spradling, M. Stapleton, R. Strong, E. Sun, Rob Svirskas, C. Tector, R. Turner, E. Venter, A. H. Wang, X. Wang, Z. Y. Wang, D. Wassarman, G. Weinstock, J. Weissenbach, S. Williams, WoodageT, K. Worley, D. Wu, S. Yang, Q. Yao, J. Ye, R. Yeh, J. Zaveri, M. Zhan, G. Zhang, Q. Zhao, L. Zheng, X. H. Zheng, F. Zhong, W. Zhong, X. Zhou, S. Zhu, X. Zhu, H. Smith, R. Gibbs, E. Myers, G. Rubin, J. Venter +194 moresemanticscholar +1 more sourceCytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway
Molecular Oncology, EarlyView.Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock +10 morewiley +1 more sourceTowards personalizing treatment strategies in mCRPC: can dual-tracer PET-CT provide insights into tumor biology, guide the optimal treatment sequence, and individualize decision-making (between chemotherapy, second-generation anti-androgens and PSMA-directed radioligand therapy) early in the disease course? [PDF]
, 2019 Sandip Basu, Rahul V. Parghane, Sonam Suman, Amit Joshi, Kumar Prabhash, Ganesh Bakshi, Sharmila Banerjee +6 moreopenalex +1 more sourceClass IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer
Molecular Oncology, EarlyView.HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio +13 morewiley +1 more sourceIn vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations
Molecular Oncology, EarlyView.Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow +10 morewiley +1 more source
